AbbVie retreats as Galapagos offers mixed PhII CF data, leaving a major alliance in peril — Vertex shares surge
Galapagos $GLPG outlined some distinctly mixed results from its Phase II study of its C2 corrector GLPG2737 for cystic fibrosis Thursday afternoon, managing to boost the prospects of rival Vertex in the process.
While Galapagos said that the drug — combined with a stable dose of Vertex’s Orkambi — had hit a significant decrease of 19.6 mmol/L (p=0.02) on sweat chloride from baseline, there was only a positive trend in ppFEV1. “The mean absolute change from baseline in ppFEV1 for the GLPG2737 treatment arm versus placebo through day 28 was 3.4% (p=0.08).”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
